SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-20-020801
Filing Date
2020-10-06
Accepted
2020-10-06 16:07:08
Documents
13
Period of Report
2020-10-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K acrx20201005_8k.htm   iXBRL 8-K 27928
  Complete submission text file 0001437749-20-020801.txt   160988

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA acrx-20201001.xsd EX-101.SCH 3700
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE acrx-20201001_def.xml EX-101.DEF 11586
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrx-20201001_lab.xml EX-101.LAB 15466
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrx-20201001_pre.xml EX-101.PRE 11740
6 EXTRACTED XBRL INSTANCE DOCUMENT acrx20201005_8k_htm.xml XML 2565
Mailing Address 351 GALVESTON DRIVE REDWOOD CITY CA 94063
Business Address 351 GALVESTON DRIVE REDWOOD CITY CA 94063 650-216-3500
ACELRX PHARMACEUTICALS INC (Filer) CIK: 0001427925 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35068 | Film No.: 201226851
SIC: 2834 Pharmaceutical Preparations